Latest Orion Pharma News & Updates

See the latest news and media coverage for Orion. We track all announcements, press releases, and industry mentions in real time, all in one place.

Orion Pharma (Orion)

Finnish pharmaceutical company

Latest news about Orion Pharma (Orion)

April 23 Orion

Orion Group releases Q1 2026 interim report

Net sales rose 17.8% to EUR 417.7 million; operating profit up 47.3% to EUR 114.8 million. 2026 outlook specified higher.
April 23 Orion

Orion Pharma initiates TEADCO Phase 1b/2 basket trial for ODM-212

The trial evaluates ODM-212 with standard treatments in advanced mesothelioma, KRAS G12C mutated NSCLC, and pancreatic cancer. It assesses efficacy, safety, and tolerability.
April 20 Orion

Orion Pharma’s ODM-212 receives FDA orphan drug designation for mesothelioma

The designation applies to the investigational pan-TEAD inhibitor in Phase 2 trials for rare cancers. It qualifies Orion for tax credits, fee exemptions, and market exclusivity.
April 10 Orion

Orion publishes Interim Report for January–March 2026

A webcast and conference call for analysts, investors, and media occur on 23 April 2026 at 14.00 EEST.

Today Yahoo Finance

Orion Corporation: Managers’ transactions – Karen Lykke Sørensen

ORION CORPORATION MANAGERS’ TRANSACTIONS 4 MAY 2026 at 16.00 EEST Orion Corporation: Managers’ transactions – Karen Lykke Sørensen Orion Corporation has received the following disclosure...
April 29 Turun Sanomat

Another major investment in the pharmaceutical sector in Turku: Orion to build a new laboratory

The growth of operations requires more space, and in addition, the old laboratory will be renovated. In Turku's quality control unit, all active pharmaceutical ingredients are tested.
April 27 Yahoo Finance

Composition of the Nomination Committee of Orion Corporation

OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE27 APRIL 2026 at 12:00 EEST Composition of the Nomination Committee of Orion Corporation The Board...
April 23 Yahoo Finance

Orion Oyj (ORINF) Q1 2026 Earnings Call Highlights: Robust Growth and Strategic Outlook

Orion Oyj (ORINF) reports significant sales and profit growth, driven by innovative medicines and sustainability efforts, while adjusting its financial outlook for the year.

Never miss news about Orion

Track Orion and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Browse news for competitors to Orion and other trending companies.